Valion Bio appoints Lisa Wolf President/COO, adds two directors, raises $7.7M from 3i

Valion Bio, Inc.

Lisa Wolf becomes President and COO, retains CFO role; former CEO Michael K. Handley has departed.
Jared Malbin (Lucid Capital Markets COO) and Thomas Jensen (Allarity Therapeutics CEO) joined the board.
Letter agreement with 3i: issued 100 Series B and 7,637 Series C preferred plus warrants for $7.737M; $1.5M cash to company.
Warrants cover 1,053,969 shares at $3.62 exercise; $6.137M retained by 3i to satisfy overdue cash true-up.
Lead asset Entolimod targets projected $7.8B Acute Radiation Syndrome market by 2032.

item 1.01 item 3.02 item 5.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.